Gravitate Health secures an 8-month extension: Going beyond the project's initial goals and ambitions
The extension provides a greater opportunity to maximise the project’s impact by allowing more time to gather data from our empirical work and to expand our external stakeholder engagement activities and post-project sustainability efforts. To achieve this, we are strengthening several specific areas:
- patient and citizen engagement via tools and services designed to support safe medicines use;
- extending collaboration with EMA, other regulators, and initiatives to accelerate progress;
- contributing to the wider digital transformation of healthcare within the EU, with alignment to key initiatives for health data use, cross-border mobility, the EHDS, and the EEHRxF; and
- advancing international standards work.
The external digital landscape in which Gravitate Health is engaged is highly dynamic, and extending the project as proposed will be key to maximising its ultimate impact and value.
Gravitate Health has delivered value in many areas, and there is currently no other EU-wide initiative operating in the same space. Regulators are investing in ePI and recognise the need for an EU-wide solution (as a complement to national solutions) to ensure that ePI for all medications is readily accessible to citizens.
With the new closing date, the project will have greater opportunity to embed its contributions into the evolving digital health information landscape, further exploit the potential advantages of recent innovative technologies such as generative AI and deepen its participation in EU initiatives for the digital transformation of healthcare. This includes leveraging opportunities associated with revisions to EU pharmaceutical legislation and advancing towards ‘digital first’ approaches.
